Preoperative Radiotherapy with a Simultaneous Integrated Boost Compared to Chemoradiotherapy for cT3-4 Rectal Cancer: Long-Term Results of a Multicenter Randomized Study
Authors:
- Benedikt EngelsBEBenedikt Engels
- Antonino De PaoliAntonino De Paoli
- Elena DelmastroEDElena Delmastro
- Fernando MunozFMFernando Munoz
- Stefano VaggeStefano Vagge
- Darius NorkusDNDarius Norkus
- Hendrik EveraertHEHendrik Everaert
- Gianna TabaroGTGianna Tabaro
- Elisabetta GariboldiElisabetta Gariboldi
- Umberto RicardiURUmberto Ricardi
- Eugenio BorsattiEBEugenio Borsatti
- Pietro GabrielePGPietro Gabriele
Open Access
Abstract
Background: Preoperative chemoradiotherapy (CRT) is the standard treatment for T3-4 rectal cancer. Here, we compared image-guided and intensity-modulated RT (IG-IMRT) with a simultaneous integrated boost (SIB) (instead of concomitant chemotherapy) versus CRT in a multi-centric randomized trial. Methods: cT3-4 rectal cancer patients were randomly assigned to receive preoperative IG-IMRT 46 Gy/23 fractions plus capecitabine 825 mg/m² twice daily (CRT arm) or IG-IMRT 46 Gy/23 fractions with an SIB to the rectal tumor up to a total dose of 55.2 Gy (RTSIB arm). Results: A total of 174 patients were randomly assigned between April 2010 and May 2014. Grade 3 acute toxicities were 6% and 4% in the CRT and RTSIB arms, respectively. The mean fractional change in SUVmax at 5 weeks after completion of preoperative RT were −55.8% (±24.0%) and −52.9% (±21.6%) for patients in the CRT arm and RTSIB arm, respectively (p = 0.43). The pathologic complete response rate was 24% with CRT compared to 14% with RTSIB. There were no differences in 5-year overall survival (OS), progression-free survival (PFS) or local control (LC). Conclusions: The preoperative RTSIB approach was not inferior to CRT in terms of metabolic response, toxicity, OS, PFS and LC, and could be considered an available option for patients unfit for fluorouracil-based CRT.Keywords
This publication has 35 references indexed in Scilit:
- Radiation Dose-Response Model for Locally Advanced Rectal Cancer After Preoperative Chemoradiation TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trialThe Lancet Oncology, 2012
- Radiation Therapy Oncology Group 0247: A Randomized Phase II Study of Neoadjuvant Capecitabine and Irinotecan or Capecitabine and Oxaliplatin With Concurrent Radiotherapy for Patients With Locally Advanced Rectal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III TrialJournal of Clinical Oncology, 2011
- Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2Journal of Clinical Oncology, 2010
- Improving Local Control in Rectal Cancer: Radiation Sensitizers or Radiation Dose?Journal of Clinical Oncology, 2010
- Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiotherapy in Nonresectable Rectal CancerJournal of Clinical Oncology, 2008
- Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203Journal of Clinical Oncology, 2006
- Preoperative versus Postoperative Chemoradiotherapy for Rectal CancerNew England Journal of Medicine, 2004
- Morphometric analysis of white matter lesions in MR images: method and validationIEEE Transactions on Medical Imaging, 1994